Celgene Co. (CELG) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in shares of Celgene Co. (NASDAQ:CELG) by 0.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,847,096 shares of the biopharmaceutical company’s stock after acquiring an additional 7,356 shares during the quarter. Dimensional Fund Advisors LP owned about 0.23% of Celgene worth $269,312,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. increased its stake in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI increased its stake in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the period. Robecosam AG purchased a new position in shares of Celgene during the third quarter valued at approximately $114,000. Guidant Wealth Advisors purchased a new position in shares of Celgene during the third quarter valued at approximately $119,000. Finally, Motco increased its stake in shares of Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the period. Institutional investors own 78.93% of the company’s stock.

Several research firms have recently issued reports on CELG. Mizuho reaffirmed a “buy” rating and issued a $128.00 price target on shares of Celgene in a research note on Sunday, February 4th. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. Cantor Fitzgerald reissued a “hold” rating and issued a $112.00 target price on shares of Celgene in a report on Monday, January 29th. SunTrust Banks reissued a “buy” rating and issued a $139.00 target price (up from $127.00) on shares of Celgene in a report on Friday, January 26th. Finally, Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 target price on the stock in a report on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $130.35.

In other news, insider Mark J. Alles purchased 3,260 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the purchase, the insider now owns 178,904 shares in the company, valued at $16,441,277.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Shares of Celgene Co. (NASDAQ CELG) traded up $1.49 on Friday, reaching $92.51. The company’s stock had a trading volume of 10,465,217 shares, compared to its average volume of 8,240,000. The company has a debt-to-equity ratio of 2.29, a quick ratio of 3.52 and a current ratio of 4.99. Celgene Co. has a fifty-two week low of $88.32 and a fifty-two week high of $147.17. The stock has a market capitalization of $69,580.00, a PE ratio of 25.63, a price-to-earnings-growth ratio of 0.66 and a beta of 1.49.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. During the same quarter last year, the business posted $1.61 earnings per share. The firm’s revenue was up 16.9% on a year-over-year basis. equities research analysts forecast that Celgene Co. will post 7.68 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Celgene Co. (CELG) Shares Bought by Dimensional Fund Advisors LP” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://stocknewstimes.com/2018/02/11/celgene-co-celg-position-raised-by-dimensional-fund-advisors-lp.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply